[Diagnosis and classification of pulmonary hypertension].
Pulmonary hypertension (PH) has been defined as an increase in mean pulmonary arterial pressure (mPAP) > or = 25 mmHg at rest as assessed by right heart catheterisation (RHC). Precapillary pulmonary hypertension is defined by an increase in mPAP > or =25 mmHg and a pulmonary capillary wedge pressure (PCWP)< or =15 mmHg associated with a normal or reduced cardiac output. No definition for PH on exercise as assessed by RHC can be provided at the present time. In group 1 pulmonary arterial hypertension (PAH), the term "familial PAH" has been replaced by "heritable PAH". Heritable forms of PAH include clinically sporadic idiopathic PAH with germline mutations and clinical familial cases with or without identified germline mutations. Schistosomiasis and chronic haemolytic anaemia have been included among the group of associated PAH. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis have been individualized and designated as clinical group 1'.
Montani
David
D
Université Paris-Sud XI, Faculté de Médecine, 94276 Le Kremlin-Bicêtre, France.
Chaouat
Ari
A
D030301:Activin Receptors, Type II / Q000235:genetics; D000743:Anemia, Hemolytic / Q000150:complications; D052006:Bone Morphogenetic Protein Receptors, Type II / Q000235:genetics; D006328:Cardiac Catheterization; D015984:Causality; D005277:Fenfluramine / Q000009:adverse effects; D020022:Genetic Predisposition to Disease / Q000235:genetics; D018095:Germ-Line Mutation / Q000235:genetics; D006331:Heart Diseases / Q000150:complications; D006391:Hemangioma / Q000150:complications; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification* / Q000175:diagnosis* / Q000209:etiology* / Q000503:physiopathology; D008175:Lung Neoplasms / Q000150:complications; D011655:Pulmonary Embolism / Q000150:complications; D011668:Pulmonary Veno-Occlusive Disease / Q000150:complications; D011669:Pulmonary Wedge Pressure; D012552:Schistosomiasis / Q000150:complications; D018490:Serotonin Agents / Q000009:adverse effects; D012720:Severity of Illness Index
D018490:Serotonin Agents; D005277:Fenfluramine; C425364:ACVRL1 protein, human; D030301:Activin Receptors, Type II; D052006:Bone Morphogenetic Protein Receptors, Type II